To determine the diagnostic value of mean platelet volume in local Chinese with acute coronary syndrome who attended emergency department in Hong Kong. Design: cross sectional study. Setting: emergency department of a local hospital. Methods: Data of adult Chinese patients presented to a local emergency department (ED) with chest pain were retrieved from 1st October 2010 to 31st October 2010. Blood test for mean platelet volume (MPV) was drawn, and its relationship with development of acute coronary syndrome (ACS) was studied. Results: 429 patients were enrolled and 77 (17.9%) of them were diagnosed to have ACS. Non-statistically significant trend of elevated MPV was observed in ACS group vs non ACS group (8.0±1.12 fL vs. 7.8±1.03 fL, p=0.06). Subgroup analysis was performed on patients presented within 4 hours of onset of chest pain. Both MPV and adjusted MPV were higher in ACS group (p<0.03, and p<0.01 respectively). Cut-off 6.97 fL of adjusted MPV has the best performance, with 90.91% sensitivity and 22.86% specificity. Conclusions: Adjusted-MPV is higher in ACS within 4 hour of presentation, but the discriminating power is not adequate. Further study is needed to validate the cut-off level and its clinical applicability. ( Hong Kong j.emerg.med. 2016;23:273-278) 2010 10 1 2010 10 31 ED MPV ACS 429 77 17.9 ACS ACS ACS MPV 8.0±1.12 fL vs 7.8±1.03 fL p=0.06 4 ACS MPV MPV p<0.03 p<0.01 MPV 6.97 fL 90.91 22.86 4 ACS MPV
Introduction
Acute chest pain was a common presenting symptom in emergency department (ED). Acute coronary syndrome was an important diagnosis not to be missed. It is challenging for emergency physician to make a rapid and accurate diagnosis in such scenario.
Platelet activation was a hallmark of acute coronary syndrome (ACS). Platelet size was measured as mean platelet volume (MPV). Large platelets express higher levels of pro-coagulatory surface proteins, such as glycoprotein IIb/IIIa, and have a higher thromboxane A2 level. Large Platelet was more reactive and aggregate faster. Thus they have higher potential to form thrombus. 1, 2 ACS, including unstable angina, non-ST elevated myocardial infarction (NSTEMI), and ST elevated myocardial infarction (STEMI). Unstable angina and N S T E M I a re d u e t o e r o s i o n o r r u p t u re o f atherosclerotic plaques in coronary arteries, platelet activation and platelet-rich thrombus formation. STEMI is due to thrombus occlusion to coronary vessel for a prolonged period.
Previous studies found MPV increase in early phase of ACS. Upon 1983, Martin et al conducted a clinical study demonstrating an increase in mean platelet volume within 12 hours of admission for patients with acute myocardial infarction (AMI). 3 Clinical Studies in recent years had demonstrated higher MPV was associated with AMI among Caucasian , India and Turkey. 1, [4] [5] [6] [7] Recently, Chu et al conducted a study in Taiwan. The study demonstrated that MPV was significantly associated with ACS in Chinese patients with acute chest pain and was an early, reliable and independent predictor. 8 The study had recruited patients presenting to ED with onset of chest pain within 4 hours. The blood sample was analysed within 20 minutes after blood sample taken. The best cut-off value was 10.35 fL (sensitivity 78.3%; specificity 74.6%). The corresponding area under the receiver operating characteristic curve (ROC) for MPV in predicting ACS in patients with acute chest pain was 0.800 (95% CI 0.736 to 0.864). 8 We conducted this study to determine the diagnostic value of MPV level for ACS patient in the local Chinese population in Hong Kong.
Subjects and methods

Study design
This was a cross sectional study to assess whether MPV was able to predict ACS from patients with acute chest pain. The study protocol was approved by the Kowloon West Cluster Ethics Committee of the hospital.
Setting
The study took place in the emergency department of Yan Chai Hospital (YCH). YCH is a community based hospital. In the year of our study recruitment, the number of annual ED visiting patients was 130,000.
Population
We searched the data from the electronic hospital database, the Clinical data analysis and reporting systems (CDARS) of Hospital Authority, from 1st October 2010 to 31st October 2010. Patients who attended ED together with Troponin I (TnI) taken were identified. The blood test for TnI was taken either in ED or after admission. All the ED records of these patients were reviewed. Patients presenting with chest pain were sorted out and recruited. Then ED records, clinical notes, ECG, laboratory result and imaging findings were analysed. The clinical records of subsequent follow up, re-attendance to ED within 3 months of first presentation were reviewed. Then the recruited patients were classified into ACS, and non-ACS.
Exclusion criteria included patients with traumatic chest pain, severe hepatic impairment, renal impairment, documented malignancy, myeloproliferative disorders or on anticoagulants.
Outcome definition
AMI was diagnosed based on the following criteria, which were defined by the American College of Cardiology. 9 They were as the followings: detection of a rise and/or a fall in cardiac biomarkers (preferably troponin) with at least one value above the 99th percentile of the upper reference limit together with evidence of myocardial ischaemia based on at least one of the following: Unstable angina (UA) was diagnosed based on definition from the American Heart Association: 10 1. New onset of severe angina or accelerated angina; 2. Angina at rest within past month but not within preceding 48 hour (angina at rest, subacute); 3. Angina at rest within 48 hour (angina at rest, acute).
ACS was defined as either AMI or UA.
Outcome measurement
The first biochemical (TnI) and haematologic tests (MPV) done on the recruited patients were analysed. The laboratory of our hospital using specific machine calculated both MPV and TnI in this study. The reference range for TnI and MPV were <0.04 (ng/mL) and 7-10(fL) respectively (as suggested by the laboratory of our hospital during the study period). The diagnosis of AMI, UA and non-ACS were made by the investigators according the following clinical data: history based on symptoms, ECG, troponin I level, cardiac angiography result, clinical notes of follow up and any ED re-attendance within 3 months.
Statistical methods
Statistical analysis was performed using SPSS statistical software (version 19.0, SPSS). The results were presented as mean ± standard deviation (SD) or frequency (in percentage). χ 2 test or Fisher exact test, was used for analysis of categorical variables. C o n t i n u o u s v a r i a b l e s w e re c o m p a re d u s i n g independent t-test if normal distribution; otherwise, Mann-Whitney U test. A p value of <0.05 was considered as statistically significant.
Results
During the period of the study, 529 patients were admitted via ED due to chest pain. One hundred patients were excluded. A total of 429 patients were recruited in our study (Figure 1 ). ACS was diagnosed in 77 patients (17.9%). Among these patient, 31 patients (7.2%) had AMI and 46 (10.7%) had UA. The demographic and clinical characteristics of the study patients were shown in Table 1 . Patients in ACS group have significantly more cardiovascular risk factors and are on anti-platelet treatment. More leucocytosis was observed in ACS group and AMI group. Initial TnI was higher in ACS group (Table 2) . There was a trend of increased MPV in ACS group despite statistically insignificant (8.0±1.12 fL vs. 7.8± 1.03 fL; p=0.06).
Subgroup analysis
In the Chu et al study, patients presented within 4 hours of onset of chest pain were selected, and the blood sample was analysed within 20 minutes after blood sample taken. 8 Subgroup analysis has been performed on patients presented within 4 hours of onset of chest pain (see Table 3 ). A total of 46 patients were identified The adjusted-MPV (MPVa) was also higher in ACS group (9.11±0.47 fL vs 8.11±0.15 fL; p<0.01). The ROC curve of MPVa and TnI for predicting ACS within 4 hours was shown in Figure 2 . Cut-off was the best at 6.97 fL, with 90.91% sensitivity and 22.86% specificity. Troponin I had an inferior performance if the clinical presentation was within 4 hours and cutoff >0.03 ng/mL was used (45.45% sensitivity and 91.43% specificity), while adjusted-MPV could identify 5 more TnI negative cases with confirmed ACS. The area under curve(AUC) of MPVa was 0.65, TnI seems to be a better choice with AUC 0.89. However, using the cut-off below 0.04 would be problematic in conventional TnI due to issue of coefficient of variance (CV) >10%. Unless high sensitivity troponin could be used, the cut off at 0.04 would be the only reliable cut-off point in conventional TnI. Therefore, MPVa could be useful clinically for predicting ACS with chest pain onset less than 4 hours, but the discriminating power alone is not adequate. MPVa would not change our clinical practice in early ACS.
Discussion
Acute chest pain was one of the most common presentations to ED. ED physicians were challenged to make a rapid and accurate diagnosis to prevent missing any major cardiac events. In current practice, patient was put under investigations including ECG and cardiac marker. However, initial troponin and ECG may not be sensitive enough to detect ACS for those patients presenting to the ED at early stage. Serial ECG and troponin were required to avoid discharging patient with ACS. MPV was studied to see if it could be an early and independent marker for accurate diagnosis of ACS in ED.
C h u e t a l , i n Ta i w a n f o u n d M P V w a s a n independent predictor of ACS in patients within 4 hours of the onset of chest pain. MPV in the ACS group was significantly higher than in the non-ACS group (10.86±0.86 fL vs. 9.86±0.76 fL, p<0.001). 9 However in our study, we found that MPV was only slightly higher in ACS group and the difference was statistically insignificant (p=0.06; Table 2 ).
Previous study showed that the platelet will expand in size while stored in EDTA medium, and thus MPV will increase with time. 8, 10 To minimise this effect, Chu et al study standardised the analysis within 20 minutes after blood collection. 8 However, it was not feasible in our retrospective study, and the time interval varied greatly. The speed of platelet swelling slowed down after 2 hours. Therefore, adjustment of MPV was made according to O'Malley's data. 11 The sensitivity and specificity profile improved after adjustment.
Even after the adjustment, there was still some difference between our results and result of Chu et al.
In the ACS group, adjusted-MPV in our study was 9.11±0.47 fL vs 10.86±0.86 fL in Chu's study. 8 The kinetics of MPV in ACS was not well understood. Previous studies suggested that the increase in MPV persisted 6 months after AMI. 3 The time of peak level of MPV in ACS was not known. Further study on serial MPV in ACS patients should be done. In order to use MPV as a clinical diagnostic tool for ACS, the relationship curve of time and MPV should be known. 
Limitations
The study design was a retrospective cohort study. It was subjected to selection and recall biases. Patients presented to ED without taken TnI (neither in ED nor in-patient) were not selected; especially those with missing diagnosis of ACS were not included in our study. Not all patients underwent further imaging At the beginning of patient recruitment, we recruited patients with chest pain onset within 4 hours, but the time between onset of chest pain and attending ED for most patients was not clearly documented. There would be too many patients excluded if we follow this inclusion criterion. Secondly, the time between blood sample collection and laboratory analysis was variable, only very few samples were analysed within 20 minutes. For these reasons, adjustment was made for MPV. However time adjusted-MPV has not yet been validated by other studies.
Conclusion
Our findings show that difference of adjusted MPV is present among ACS and non ACS group in our locality. MPV is a simple, readily available and inexpensive laboratory measurement. However, the discriminating power of MPV is not adequate if being used alone. Further studies will be required for determining the diagnostic value of MPV for predicting ACS.
